Tag: injuctions

1
Pendulum Swings in Favour of Generic/Biosimilar Companies at Interlocutory Stage in AU

Pendulum Swings in Favour of Generic/Biosimilar Companies at Interlocutory Stage in AU

By Naomi Pearce

FCA Confirms Commonwealth may Claim Relief Under “Usual Undertakings as to Damages”

The much anticipated Court of Appeal decision in Commonwealth of Australia v Sanofi ¹ was handed down on Monday.  The decision is a win for the Commonwealth, and for generic/biosimilar companies in Australia, and (if upheld in any appeal) will result in Sponsors adopting a more circumspect approach to seeking interlocutory injunctions for patent infringement in Australia.

Except where a generic/biosimilar applicant has “cleared the way” (cleared any patent impediments to launch through the Courts in Australia) or all relevant patents have expired, interlocutory injunctions are routinely sought by the Sponsor, and are routinely granted.

Read More

Copyright © 2020, K&L Gates LLP. All Rights Reserved.